Keros Therapeutics (NASDAQ:KROS) Downgraded by Cantor Fitzgerald to “Neutral”

Cantor Fitzgerald cut shares of Keros Therapeutics (NASDAQ:KROS) from an overweight rating to a neutral rating in a research note released on Tuesday, Marketbeat.com reports.

A number of other brokerages have also commented on KROS. Oppenheimer lowered their target price on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research note on Thursday, January 16th. William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Piper Sandler lowered their target price on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday, January 17th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Finally, Jefferies Financial Group assumed coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $52.56.

Keros Therapeutics Trading Up 5.1 %

Shares of Keros Therapeutics stock opened at $11.41 on Tuesday. The business’s fifty day simple moving average is $35.23 and its 200 day simple moving average is $46.97. The firm has a market capitalization of $462.22 million, a P/E ratio of -2.19 and a beta of 1.43. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.33) EPS. Analysts predict that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KROS. Renaissance Technologies LLC bought a new stake in shares of Keros Therapeutics during the 2nd quarter valued at $654,000. XTX Topco Ltd purchased a new position in Keros Therapeutics during the second quarter worth about $228,000. Point72 DIFC Ltd purchased a new position in Keros Therapeutics during the second quarter worth about $802,000. Squarepoint Ops LLC purchased a new position in Keros Therapeutics during the second quarter worth about $906,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics during the second quarter worth about $128,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.